相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
David Capper et al.
BRAIN PATHOLOGY (2010)
IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip
Christian Frezza et al.
CANCER CELL (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network
J. Tonn et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
被撤回的出版物: Marker-independent identification of glioma-initiating cells (Retracted article. See vol. 10, pg. 1035, 2013)
Virginie Clement et al.
NATURE METHODS (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma
Judith A. Schwartzbaum et al.
NEURO-ONCOLOGY (2010)
O-6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Alba A. Brandes et al.
NEURO-ONCOLOGY (2010)
Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades
Iris Lavon et al.
NEURO-ONCOLOGY (2010)
Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas
Bo-Lin Liu et al.
NEURO-ONCOLOGY (2010)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma
Myung Jin Son et al.
CELL STEM CELL (2009)
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
Amy B. Heimberger et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Limits of CD133 as a marker of glioma self-renewing cells
Virginie Clement et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome
Sophie Shnaper et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
Stuart A. Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Emerging functions of microRNAs in glioblastoma
Sean Lawler et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A. G. Essers et al.
NATURE (2009)
P16 PROMOTER METHYLATION IN THE SERUM AS A BASIS FOR THE MOLECULAR DIAGNOSIS OF GLIOMAS
Toshihiko Wakabayashi et al.
NEUROSURGERY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
Improving Seroreactivity-Based Detection of Glioma
Nicole Ludwig et al.
NEOPLASIA (2009)
Epidermal growth factor receptor inhibitors in neuro-oncology: Hopes and disappointments
Alba A. Brandes et al.
CLINICAL CANCER RESEARCH (2008)
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
Roberto Pallini et al.
CLINICAL CANCER RESEARCH (2008)
Stem cell-related Self-Renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
Anastasia Murat et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
CD133 Is a Marker of Bioenergetic Stress in Human Glioma
Corinne E. Griguer et al.
PLOS ONE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas
Eva M. Grasbon-Frodl et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Robert B. Jenkins et al.
CANCER RESEARCH (2006)
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
Adilia Hormigo et al.
CLINICAL CANCER RESEARCH (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Serum YKL-40, a new prognostic biomarker in cancer patients?
JS Johansen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma
KD Weaver et al.
CANCER INVESTIGATION (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Identification of human brain tumour initiating cells
SK Singh et al.
NATURE (2004)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
